Effect	0	6	O
of	7	9	O
estrogen	10	18	B-Drug_or_compound
and	19	22	O
progesterone	23	35	B-Drug_or_compound
on	36	38	O
macrophage	39	49	B-Cell
activation	50	60	O
during	61	67	O
wound	68	73	O
healing	74	81	O
.	81	82	O

Age	84	87	O
-	87	88	O
related	88	95	O
impaired	96	104	O
wound	105	110	O
healing	111	118	O
leads	119	124	O
to	125	127	O
substantial	128	139	O
morbidity	140	149	O
and	150	153	O
mortality	154	163	O
along	164	169	O
with	170	174	O
a	175	176	O
large	177	182	O
financial	183	192	O
burden	193	199	O
to	200	202	O
health	203	209	O
services	210	218	O
.	218	219	O

There	220	225	O
is	226	228	O
accumulating	229	241	O
evidence	242	250	O
that	251	255	O
the	256	259	O
tissue	260	266	B-Tissue
damage	267	273	O
associated	274	284	O
with	285	289	O
chronic	290	297	O
wounds	298	304	O
is	305	307	O
initiated	308	317	O
and	318	321	O
propagated	322	332	O
by	333	335	O
an	336	338	O
inappropriately	339	354	O
excessive	355	364	O
inflammatory	365	377	O
response	378	386	O
.	386	387	O

Research	388	396	O
on	397	399	O
age	400	403	O
-	403	404	O
related	404	411	O
impaired	412	420	O
wound	421	426	O
healing	427	434	O
suggests	435	443	O
that	444	448	O
the	449	452	O
decline	453	460	O
in	461	463	O
sex	464	467	B-Drug_or_compound
steroid	468	475	I-Drug_or_compound
hormones	476	484	I-Drug_or_compound
with	485	489	O
age	490	493	O
may	494	497	O
have	498	502	O
a	503	504	O
substantial	505	516	O
influence	517	526	O
on	527	529	O
the	530	533	O
inflammatory	534	546	O
response	547	555	O
in	556	558	O
vivo	559	563	O
.	563	564	O

Topical	565	572	O
and	573	576	O
systemic	577	585	O
estrogen	586	594	B-Drug_or_compound
treatments	595	605	O
have	606	610	O
shown	611	616	O
an	617	619	O
increased	620	629	O
rate	630	634	O
of	635	637	O
healing	638	645	O
by	646	648	O
reducing	649	657	O
inflammation	658	670	O
,	670	671	O
however	672	679	O
the	680	683	O
underlying	684	694	O
mechanisms	695	705	O
are	706	709	O
little	710	716	O
understood	717	727	O
.	727	728	O

In	729	731	O
vitro	732	737	O
studies	738	745	O
also	746	750	O
suggest	751	758	O
progesterone	759	771	B-Drug_or_compound
may	772	775	O
play	776	780	O
a	781	782	O
role	783	787	O
in	788	790	O
modulating	791	801	O
inflammation	802	814	O
.	814	815	O

Macrophages	816	827	B-Cell
are	828	831	O
essential	832	841	O
mediators	842	851	O
of	852	854	O
inflammation	855	867	O
and	868	871	O
wound	872	877	O
healing	878	885	O
.	885	886	O

Macrophages	887	898	B-Cell
can	899	902	O
be	903	905	O
activated	906	915	O
in	916	918	O
a	919	920	O
classical	921	930	O
or	931	933	O
alternative	934	945	O
manner	946	952	O
in	953	955	O
parallel	956	964	O
with	965	969	O
the	970	973	O
T	974	975	B-Cell
(	975	976	I-Cell
H	976	977	I-Cell
)	977	978	I-Cell
1	978	979	I-Cell
/	979	980	O
T	980	981	B-Cell
(	981	982	I-Cell
H	982	983	I-Cell
)	983	984	I-Cell
2	984	985	I-Cell
dichotomy	986	995	O
,	995	996	O
respectively	997	1009	O
.	1009	1010	O

Using	1011	1016	O
a	1017	1018	O
murine	1019	1025	B-Organism
incisional	1026	1036	O
wound	1037	1042	O
healing	1043	1050	O
model	1051	1056	O
this	1057	1061	O
study	1062	1067	O
was	1068	1071	O
carried	1072	1079	O
out	1080	1083	O
to	1084	1086	O
investigate	1087	1098	O
the	1099	1102	O
roles	1103	1108	O
of	1109	1111	O
estrogen	1112	1120	B-Drug_or_compound
and	1121	1124	O
progesterone	1125	1137	B-Drug_or_compound
on	1138	1140	O
macrophage	1141	1151	B-Cell
activation	1152	1162	O
during	1163	1169	O
the	1170	1173	O
wound	1174	1179	O
healing	1180	1187	O
response	1188	1196	O
.	1196	1197	O

Our	1198	1201	O
findings	1202	1210	O
suggest	1211	1218	O
with	1219	1223	O
a	1224	1225	O
reduction	1226	1235	O
of	1236	1238	O
steroid	1239	1246	B-Drug_or_compound
hormones	1247	1255	I-Drug_or_compound
following	1256	1265	O
ovariectomy	1266	1277	O
,	1277	1278	O
alternatively	1279	1292	O
activated	1293	1302	O
macrophage	1303	1313	B-Cell
markers	1314	1321	O
(	1322	1323	O
Fizz1	1323	1328	B-Gene_or_gene_product
and	1329	1332	O
Ym1	1333	1336	B-Gene_or_gene_product
)	1336	1337	O
were	1338	1342	O
reduced	1343	1350	O
,	1350	1351	O
with	1352	1356	O
this	1357	1361	O
effect	1362	1368	O
being	1369	1374	O
reversed	1375	1383	O
with	1384	1388	O
the	1389	1392	O
administration	1393	1407	O
of	1408	1410	O
estrogen	1411	1419	B-Drug_or_compound
or	1420	1422	O
progesterone	1423	1435	B-Drug_or_compound
;	1435	1436	O
suggesting	1437	1447	O
that	1448	1452	O
with	1453	1457	O
the	1458	1461	O
reduction	1462	1471	O
of	1472	1474	O
steroid	1475	1482	B-Drug_or_compound
hormones	1483	1491	I-Drug_or_compound
macrophages	1492	1503	B-Cell
are	1504	1507	O
activated	1508	1517	O
in	1518	1520	O
a	1521	1522	O
classical	1523	1532	O
manner	1533	1539	O
,	1539	1540	O
promoting	1541	1550	O
inflammation	1551	1563	O
,	1563	1564	O
whereas	1565	1572	O
estrogen	1573	1581	B-Drug_or_compound
or	1582	1584	O
progesterone	1585	1597	B-Drug_or_compound
are	1598	1601	O
contributing	1602	1614	O
toward	1615	1621	O
macrophage	1622	1632	B-Cell
activation	1633	1643	O
in	1644	1646	O
an	1647	1649	O
alternative	1650	1661	O
manner	1662	1668	O
,	1668	1669	O
driving	1670	1677	O
wound	1678	1683	B-Pathological_formation
repair	1684	1690	O
,	1690	1691	O
angiogenesis	1692	1704	O
,	1704	1705	O
and	1706	1709	O
remodeling	1710	1720	O
.	1720	1721	O

